1. European Association for the Study of the Liver. 2017; EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398.
3. Terrault NA, Lok ASF, McMahon BJ, et al. 2018; Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–1599. DOI:
10.1002/hep.29800. PMID:
29405329. PMCID:
PMC5975958.
Article
4. Korean Association for the Study of the Liver (KASL). 2019; KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 25:93–159. DOI:
10.3350/cmh.2019.1002. PMID:
31185710. PMCID:
PMC6589848.
7. European Association For The Study Of The Liver. 2012; EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. DOI:
10.1016/j.jhep.2012.02.010. PMID:
22436845.
8. Yim HJ, Seo YS, Yoon EL, et al. 2013; Adding adefovir vs. switching to entecavir for Lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 33:244–254. DOI:
10.1111/liv.12036. PMID:
23295056.
Article
9. Cho EY, Yim HJ, Jung YK, et al. 2017; Management of clevudine-resistant chronic hepatitis B: a multicenter cohort study. Gut Liver. 11:129–135. DOI:
10.5009/gnl15597. PMID:
27538443. PMCID:
PMC5221870.
Article
10. Kang SH, Yim HJ, Kim HR, et al. 2014; Comparison of Lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B. J Clin Gastroenterol. 48:889–895. DOI:
10.1097/MCG.0000000000000066. PMID:
24440937.
Article
11. Kim HS, Yim HJ, Jang MK, et al. 2015; Management of entecavirresistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol. 21:10874–10882. DOI:
10.3748/wjg.v21.i38.10874. PMID:
26478678. PMCID:
PMC4600588.
Article
12. Lee S, Ahn SH, Jung KS, et al. 2017; Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with Lamivudine resistance and entecavir resistance. J Viral Hepat. 24:141–147. DOI:
10.1111/jvh.12623. PMID:
27766731.
Article
13. Park JY, Kim CW, Bae SH, et al. 2016; Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int. 36:1108–1115. DOI:
10.1111/liv.13059. PMID:
26781724.
Article
14. Lee YB, Lee JH, Lee DH, et al. 2014; Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 58:6710–6716. DOI:
10.1128/AAC.03845-14. PMID:
25155601. PMCID:
PMC4249402.
Article
15. Petersen J, Ratziu V, Buti M, et al. 2012; Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 56:520–526. DOI:
10.1016/j.jhep.2011.09.018. PMID:
22037226.
Article
16. Huang ZB, Zhao SS, Huang Y, et al. 2013; Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Clin Ther. 35:1997–2006. DOI:
10.1016/j.clinthera.2013.10.002. PMID:
24238791.
Article
17. Hutin Y, Nasrullah M, Easterbrook P, et al. 2018; Access to treatment for hepatitis B virus infection - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 67:773–777. DOI:
10.15585/mmwr.mm6728a2. PMID:
30025413. PMCID:
PMC6054001.
Article
18. 2014. Global price reporting mechanism for HIV, tuberculosis and malaria. [Internet]. World Health Organization (WHO);Geneva (CH): Available from:
www.who.int/hiv/amds/gprm/en/. cited 2020 Dec 1.
19. Kersnik J, Peklar J. 2006; Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. J Clin Pharm Ther. 31:577–583. DOI:
10.1111/j.1365-2710.2006.00776.x. PMID:
17176362.
Article
20. Hill A, Gotham D, Cooke G, et al. 2015; Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Erad. 1:103–110. DOI:
10.1016/S2055-6640(20)30484-2.
Article
21. Kim DY, Kim JH, Tak WY, et al. 2017; Baracle
® vs Baraclude
® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. Drug Des Devel Ther. 11:3145–3152. DOI:
10.2147/DDDT.S149199. PMID:
29184389. PMCID:
PMC5673034.
23. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. 2010; Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 53:449–454. DOI:
10.1016/j.jhep.2010.03.020. PMID:
20646776.
Article
24. Kitrinos KM, Corsa A, Liu Y, et al. 2014; No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 59:434–442. DOI:
10.1002/hep.26686. PMID:
23939953.
Article
25. Tenney DJ, Rose RE, Baldick CJ, et al. 2009; Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 49:1503–1514. DOI:
10.1002/hep.22841. PMID:
19280622.
Article